Trials / Completed
CompletedNCT03824171
Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers
A Randomized, Open Label, Single Dose, Crossover Study to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of AD-102 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- Male
- Age
- 19 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-102 in healthy male subjects
Detailed description
This study is to evaluate the pharmacokinetic characteristics and safety of AD-102 compared with administration of raloxifen 60 mg + Cholecalciferol 800IU in healthy male subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Raloxifene 60mg/Cholecalciferol 800IU | Raloxifene 60mg/Cholecalciferol 800IU tablet |
| DRUG | AD-102 | AD-102 Raloxefene 45mg/Cholecalciferol 800IU tablet |
Timeline
- Start date
- 2019-02-28
- Primary completion
- 2019-03-27
- Completion
- 2019-04-08
- First posted
- 2019-01-31
- Last updated
- 2019-08-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03824171. Inclusion in this directory is not an endorsement.